1,083,983 Shares in Alamar Biosciences, Inc. $ALMR Purchased by Braidwell LP

Braidwell LP acquired a new stake in shares of Alamar Biosciences, Inc. (NASDAQ:ALMR) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 1,083,983 shares of the company’s stock, valued at approximately $29,365,000.

Separately, Wellington Management Group LLP bought a new position in Alamar Biosciences in the 2nd quarter worth about $12,407,000.

Alamar Biosciences Stock Performance

NASDAQ ALMR opened at $30.49 on Thursday. Alamar Biosciences, Inc. has a one year low of $18.84 and a one year high of $38.54. The company has a quick ratio of 10.23, a current ratio of 11.85 and a debt-to-equity ratio of 0.03. The stock has a market cap of $2.12 billion and a P/E ratio of -15.56. The firm’s 50-day simple moving average is $28.50.

Alamar Biosciences (NASDAQ:ALMR) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.14. The business had revenue of $29.43 million during the quarter. Equities analysts expect that Alamar Biosciences, Inc. will post -1.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on ALMR. Bank of America started coverage on shares of Alamar Biosciences in a research note on Tuesday, May 12th. They set a “neutral” rating and a $27.00 price target for the company. TD Cowen reissued a “buy” rating on shares of Alamar Biosciences in a research note on Wednesday, July 15th. Weiss Ratings initiated coverage on Alamar Biosciences in a report on Tuesday, August 11th. They set a “sell (d+)” rating on the stock. Leerink Partners started coverage on Alamar Biosciences in a research report on Tuesday, May 12th. They set an “outperform” rating and a $35.00 target price for the company. Finally, Zacks Research upgraded Alamar Biosciences to a “hold” rating in a report on Wednesday, May 13th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Alamar Biosciences currently has a consensus rating of “Hold” and a consensus price target of $31.80.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.